摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-苯氧基哌啶 | 3202-33-3

中文名称
4-苯氧基哌啶
中文别名
4-苯氧基哌嗪
英文名称
4-phenoxypiperidine
英文别名
4-phenoxy-1,2,3,6-tetrahydropiperidine
4-苯氧基哌啶化学式
CAS
3202-33-3
化学式
C11H15NO
mdl
MFCD04114971
分子量
177.246
InChiKey
KBYPITRKIJKGMD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    107-108°C/0.1mm
  • 密度:
    1.030±0.06 g/cm3(Predicted)
  • 闪点:
    107-108°C/0.1mm
  • 稳定性/保质期:
    遵照规定使用和储存,则不会分解。

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.454
  • 拓扑面积:
    21.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 海关编码:
    2933399090
  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H317,H319
  • 储存条件:
    应存于阴凉干燥环境之中。

SDS

SDS:31609fecc8bed4831115cbd041738e99
查看
Material Safety Data Sheet

Section 1. Identification of the substance
4-Phenoxypiperidine
Product Name:
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

Section 3. Composition/information on ingredients.
4-Phenoxypiperidine
Ingredient name:
CAS number: 3202-33-3

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H15NO
Molecular weight: 177.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-苯氧基哌啶 以75%的产率得到1-(2-Amino-benzothiazol-6-yl)-2-(4-phenoxy-piperidin-1-yl)-ethane
    参考文献:
    名称:
    Amino-benzothiazole derivatives
    摘要:
    本发明涉及式(I)的氨基苯并噻唑化合物,其中X、Y、Z和R1如规范所定义,它们的药学上可接受的盐,制备这些化合物的过程,包括这些化合物的制药组合物以及它们作为神经保护剂的用途。
    公开号:
    US06407122B1
  • 作为产物:
    描述:
    3-碘-氮杂丁烷-1-羧酸叔丁酯三氟乙酸 作用下, 以 二氯甲烷 为溶剂, 反应 4.0h, 生成 4-苯氧基哌啶
    参考文献:
    名称:
    Utility of azetidinium methanesulfonates for radiosynthesis of 3-[18F]fluoropropyl amines
    摘要:
    观察到 3-甲磺酰氧基丙基叔胺环化形成甲磺酸氮杂环丁烷。利用 3-甲磺酰氧基丙胺的热诱导环化反应制备了氮杂环丁烷甲磺酸盐。研究发现,氮杂环丁烷甲烷磺酸盐能有效地结合放射性[18F]氟化物(衰变校正产率大于 60%),从而高效合成了 3-[18F]fluoropropyl tertiary amines(3-[18F]氟丙基叔胺)。Copyright © 2004 John Wiley & Sons, Ltd. All Rights Reserved.
    DOI:
    10.1002/jlcr.884
点击查看最新优质反应信息

文献信息

  • COMPOUNDS AND USES THEREOF
    申请人:Yumanity Therapeutics, Inc.
    公开号:US20190330198A1
    公开(公告)日:2019-10-31
    The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    本发明涉及用于治疗神经系统疾病的化合物。本发明的化合物可以单独或与其他药用活性剂结合使用,用于治疗或预防神经系统疾病。
  • One-pot synthesis of 2-aminobenzoxazole derivatives using acetic acid as an electrolyte under electrochemical conditions
    作者:Tanay Ghoshal、Tarun M. Patel
    DOI:10.1007/s13738-021-02184-1
    日期:2021.9
    ammoniumbromide, sodium iodide and lithium perchlorate, but in this conversion we have removed the use of all supporting electrolytes and we have used acetic acid, which plays a dual role of opening the benzoxazole moiety and works as an electrolyte. All these electrochemical conversions were done on a electrochemical reactor prepared through a 5v mobile charger having a output current density of 0.35A.cm−2. Various
    在这项工作中,我们开发了一种以乙酸为电解质制备 2-氨基苯并恶唑的电化学方法。这种方法的主要优点是反应模式更清洁,杂质形成最少,不使用金属催化剂,原子经济性高,坚固耐用,可扩展并具有广泛的底物范围。以前,有报道称添加四丁基溴化铵、碘化钠和高氯酸锂等支持电解质进行电化学转化,但在此转化过程中,我们取消了所有支持电解质的使用,我们使用了乙酸,醋酸具有双重作用打开苯并恶唑部分并用作电解质。所有这些电化学转换都是在通过输出电流密度为 0.35A.cm-2 的 5v 移动充电器制备的电化学反应器上完成的。通过使用这种设置,各种药学相关的仲胺以高产率与苯并恶唑偶联。所有转化均在室温下进行,并且在 6 小时内观察到总转化。转换的范围从毫克到克。采用该方法制备了失眠药物Suvorexant的活性中间体。
  • [EN] CHEMOKING RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE CHIMIOKINES
    申请人:ABBOTT LAB
    公开号:WO2013010453A1
    公开(公告)日:2013-01-24
    Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.
    本文揭示了化学受体拮抗剂的化学式(I),其中G1、X1、X2和X3如规范中所定义。还描述了包含这种化合物的组合物;以及使用这种化合物和组合物治疗疾病和疾病的方法。
  • Compounds having effects on serotonin-related systems
    申请人:Eli Lilly and Company
    公开号:US05741789A1
    公开(公告)日:1998-04-21
    A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.
    一系列的杂氧烷胺类化合物是治疗与血清素再摄取和血清素1A受体有关或受其影响的疾病的有效药物。这些化合物特别适用于缓解尼古丁和烟草戒断症状,以及治疗抑郁症和其他需要使用血清素再摄取抑制剂的疾病。
  • [EN] 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS<br/>[FR] 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES ET 4-PYRAZOLYL-N-HÉTÉROARYLPYRIMIDIN-2-AMINES EN TANT QU'INHIBITEURS DE JANUS KINASE
    申请人:INCYTE CORP
    公开号:WO2009064835A1
    公开(公告)日:2009-05-22
    The present invention provides substituted bicyclic heteroaryl compounds, 5 including, for example, 4-pyrazoIyI-N-arylpyrirnidin-2-arnines and 4-pyrazolyl-N-heteroarylpyτimidin-2-amines that modulate the activity of kinases and are useful in the treatment of diseases related to activity of kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.formule :(1)
    本发明提供了取代的双环杂环芳基化合物,包括例如4-吡唑基-N-芳基吡啶-2-胺和4-吡唑基-N-杂环芳基嘧啶-2-胺,这些化合物调节激酶的活性,在治疗与激酶活性相关的疾病方面具有用处,例如免疫相关疾病、皮肤疾病、髓细胞增生性疾病、癌症和其他疾病。公式:(1)
查看更多